A multicentre, randomised, double-blind, placebo-controlled, dose-finding phase II clinical study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer

Trial Profile

A multicentre, randomised, double-blind, placebo-controlled, dose-finding phase II clinical study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2015

At a glance

  • Drugs Espindolol (Primary)
  • Indications Cachexia
  • Focus Therapeutic Use
  • Sponsors PsiOxus Therapeutics
  • Most Recent Events

    • 28 Apr 2014 New trial record
    • 13 Nov 2013 Results presented at the 7th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) Conference in December 2013.
    • 12 Nov 2013 Primary endpoint 'Bodyweight' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top